Peter E. Clark, M.D.

Professor

peter.clark@vanderbilt.edu
Faculty Appointments
Professor of Urologic Surgery
Education
M.D., Medicine, Harvard Medical School, Boston, MassachusettsB.A., Biology, Cornell University, Ithaca, New York
Office Address
A-1302 MCN
Nashville, TN 37232-2765
Research Keywords
Urologic Oncology and Molecular Biology of Kidney Cancer
Clinical Research Keywords
Urologic Oncology including cancer of the kidney, bladder, prostate, testis, and penis
Publications
Borden LS, Clark PE, Lovato J, Hall MC, Stindt D, Harmon M, M Mohler R, Torti FM. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer. Cancer. 2006 Sep 9/1/2006; 107(5): 1093-100. PMID: 16888761, DOI: 10.1002/cncr.22078, ISSN: 0008-543X.

Clark PE, Hall MC, Borden LS, Miller AA, Hu JJ, Lee WR, Stindt D, D'Agostino R, Lovato J, Harmon M, Torti FM. Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. Urology. 2006 Jun; 67(6): 1257-61. PMID: 16765186, PII: S0090-4295(05)01789-9, DOI: 10.1016/j.urology.2005.12.035, ISSN: 1527-9995.

Lockett KL, Hall MC, Clark PE, Chuang SC, Robinson B, Lin HY, Su LJ, Hu JJ. DNA damage levels in prostate cancer cases and controls. Carcinogenesis [print-electronic]. 2006 Jun; 27(6): 1187-93. PMID: 16364923, PII: bgi288, DOI: 10.1093/carcin/bgi288, ISSN: 0143-3334.

Rackley JD, Clark PE, Hall MC. Complementary and alternative medicine for advanced prostate cancer. Urol. Clin. North Am. 2006 May; 33(2): 237-46, viii. PMID: 16631462, PII: S0094-0143(05)00125-4, DOI: 10.1016/j.ucl.2005.12.007, ISSN: 0094-0143.

Gwynn ES, Clark PE. Bladder cancer. Curr Opin Oncol. 2006 May; 18(3): 277-83. PMID: 16552241, PII: 00001622-200605000-00011, DOI: 10.1097/01.cco.0000219258.75961.1a, ISSN: 1531-703X.

Rossi PJ, Clark PE, Papagikos MA, McCullough DL, Lee WR. Percentage of positive biopsies associated with freedom from biochemical recurrence after low-dose-rate prostate brachytherapy alone for clinically localized prostate cancer. Urology. 2006 Feb; 67(2): 349-53. PMID: 16461084, PII: S0090-4295(05)01206-9, DOI: 10.1016/j.urology.2005.08.047, ISSN: 1527-9995.

Gwynn ES, Clark PE, Hall MC. Recent advances in the treatment of bladder cancer. Expert Rev Anticancer Ther. 2005 Dec; 5(6): 1023-30. PMID: 16336093, DOI: 10.1586/14737140.5.6.1023, ISSN: 1744-8328.

Gwynn ES, Clark PE. Inflammatory myofibroblastic tumor associated with renal cell carcinoma. Urology. 2005 Oct; 66(4): 880. PMID: 16230166, PII: S0090-4295(05)00413-9, DOI: 10.1016/j.urology.2005.03.065, ISSN: 1527-9995.

Clark PE, Veys JA, Eskridge MR, Woodruff RD, Hall MC. Prognostic significance of clinicopathologic and deoxyribonucleic acid flow cytometric variables in non-metastatic renal cell carcinoma in the modern era. Urol. Oncol. 2005 Sep; 23(5): 328-32. PMID: 16144666, PII: S1078-1439(05)00019-0, DOI: 10.1016/j.urolonc.2005.01.017, ISSN: 1078-1439.

Clark PE, Stein JP, Groshen SG, Cai J, Miranda G, Lieskovsky G, Skinner DG. Radical cystectomy in the elderly: comparison of clincal outcomes between younger and older patients. Cancer. 2005 Jul 7/1/2005; 104(1): 36-43. PMID: 15912515, DOI: 10.1002/cncr.21126, ISSN: 0008-543X.

Clark PE, Hall MC. Contemporary management of the urethra in patients after radical cystectomy for bladder cancer. Urol. Clin. North Am. 2005 May; 32(2): 199-206. PMID: 15862617, PII: S0094-0143(05)00023-6, DOI: 10.1016/j.ucl.2005.01.004, ISSN: 0094-0143.

Borden LS, Clark PE, Hall MC. Bladder cancer. Curr Opin Oncol. 2005 May; 17(3): 275-80. PMID: 15818174, PII: 00001622-200505000-00014, ISSN: 1040-8746.

Clark PE, Stein JP, Groshen SG, Cai J, Miranda G, Lieskovsky G, Skinner DG. Radical cystectomy in the elderly: Comparison of survival between younger and older patients. Cancer. 2005 Feb 2/1/2005; 103(3): 546-52. PMID: 15630702, DOI: 10.1002/cncr.20805, ISSN: 0008-543X.

Clark PE, Farver CF, Ulchaker JC, Angermeier K. A rare case of an extra-adrenal myelolipoma arising in the renal sinus: a case report and review of the literature. ScientificWorldJournal. 2005 Jan 1/28/2005; 5: 109-17. PMID: 15702223, PII: 10.1100/tsw.2005.18, DOI: 10.1100/tsw.2005.18, ISSN: 1537-744X.

Papagikos MA, Deguzman AF, Rossi PJ, McCullough DL, Clark PE, Lee WR. Dosimetric quantifiers for low-dose-rate prostate brachytherapy: is V(100) superior to D(90)?. Brachytherapy. 2005; 4(4): 252-8. PMID: 16344254, PII: S1538-4721(05)00150-9, DOI: 10.1016/j.brachy.2005.09.001, ISSN: 1538-4721.

Clark PE, Stein JP, Groshen SG, Miranda G, Cai J, Lieskovsky G, Skinner DG. The management of urethral transitional cell carcinoma after radical cystectomy for invasive bladder cancer. J. Urol. 2004 Oct; 172(4 Pt 1): 1342-7. PMID: 15371837, PII: 00005392-200410000-00028, ISSN: 0022-5347.

Lockett KL, Hall MC, Xu J, Zheng SL, Berwick M, Chuang SC, Clark PE, Cramer SD, Lohman K, Hu JJ. The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function. Cancer Res. 2004 Sep 9/1/2004; 64(17): 6344-8. PMID: 15342424, PII: 64/17/6344, DOI: 10.1158/0008-5472.CAN-04-0338, ISSN: 0008-5472.

Kubinski DJ, Clark PE, Assimos DG, Hall MC. Utility of frozen section analysis of resection margins during partial nephrectomy. Urology. 2004 Jul; 64(1): 31-4. PMID: 15245928, PII: S0090429504003280, DOI: 10.1016/j.urology.2004.03.011, ISSN: 1527-9995.

Zagoria RJ, Hawkins AD, Clark PE, Hall MC, Matlaga BR, Dyer RB, Chen MY. Percutaneous CT-guided radiofrequency ablation of renal neoplasms: factors influencing success. AJR Am J Roentgenol. 2004 Jul; 183(1): 201-7. PMID: 15208139, DOI: 10.2214/ajr.183.1.1830201, ISSN: 0361-803X.

Clark PE, Streem SB. Endourologic management of upper tract transitional cell carcinoma. ScientificWorldJournal. 2004 Jun 6/7/2004; 4 Suppl 1: 62-75. PMID: 15349530, DOI: 10.1100/tsw.2004.49, ISSN: 1537-744X.

Clark PE, Hall MC, Miller A, Ridenhour KP, Stindt D, Lovato JF, Patton SE, Brinkley W, Das S, Torti FM. Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma. Urology. 2004 Jun; 63(6): 1061-5. PMID: 15183950, PII: S009042950400144X, DOI: 10.1016/j.urology.2004.01.035, ISSN: 1527-9995.

Borden LS, Clark PE, Hall MC. Bladder cancer. Curr Opin Oncol. 2004 May; 16(3): 257-62. PMID: 15069323, PII: 00001622-200405000-00012, ISSN: 1040-8746.

Matlaga BR, Zagoria RJ, Clark PE, Hall MC. Radiofrequency ablation of renal tumors. Curr Urol Rep. 2004 Feb; 5(1): 39-44. PMID: 14733836, ISSN: 1527-2737.

Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, Groshen S, Cote RJ, Lieskovsky G, Quinn DI, Skinner DG. Microscopic and gross extravesical extension in pathological staging of bladder cancer. J. Urol. 2004 Feb; 171(2 Pt 1): 640-5. PMID: 14713777, DOI: 10.1097/01.ju.0000108664.39035.51, ISSN: 0022-5347.

Clark PE, Torti FM. Prostate cancer and bone metastases: medical treatment. Clin. Orthop. Relat. Res. 2003 Oct; (415 Suppl): S148-57. PMID: 14600605, DOI: 10.1097/01.blo.0000093840.72468.e1, ISSN: 0009-921X.

Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, Groshen S, Lieskovsky G, Quinn DI, Raghavan D, Skinner DG. Natural history of surgically treated bladder carcinoma with extravesical tumor extension. Cancer. 2003 Sep 9/1/2003; 98(5): 955-61. PMID: 12942562, DOI: 10.1002/cncr.11569, ISSN: 0008-543X.

Borden LS, Clark PE, Hall MC. Bladder cancer. Curr Opin Oncol. 2003 May; 15(3): 227-33. PMID: 12778017, ISSN: 1040-8746.

Jia L, Kim J, Shen H, Clark PE, Tilley WD, Coetzee GA. Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms. Mol. Cancer Res. 2003 Mar; 1(5): 385-92. PMID: 12651911, ISSN: 1541-7786.

Clark PE, Irvine RA, Coetzee GA. The androgen receptor CAG repeat and prostate cancer risk. Methods Mol. Med. 2003; 81: 255-66. PMID: 12725125, DOI: 10.1385/1-59259-372-0:255, ISSN: 1543-1894.

Wilson SS, Clark PE, Stein JP. Angiomyolipoma with vena caval extension. Urology. 2002 Oct; 60(4): 695-6. PMID: 12385937, PII: S0090429502018976, ISSN: 1527-9995.

Clark PE. Urinary diversion after radical cystectomy. Curr Treat Options Oncol. 2002 Oct; 3(5): 389-402. PMID: 12194804, ISSN: 1527-2729.

Clark PE, Peereboom DM, Dreicer R, Levin HS, Clark SB, Klein EA. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology. 2001 Feb; 57(2): 281-5. PMID: 11182337, PII: S0090-4295(00)00914-6, ISSN: 1527-9995.

Clark PE, Schover LR, Uzzo RG, Hafez KS, Rybicki LA, Novick AC. Quality of life and psychological adaptation after surgical treatment for localized renal cell carcinoma: impact of the amount of remaining renal tissue. Urology. 2001 Feb; 57(2): 252-6. PMID: 11182331, PII: S0090-4295(00)00927-4, ISSN: 1527-9995.

Clark PE, Novick AC. Exophytic noninvasive growth pattern of renal angiomyolipomas: implications for nephron sparing surgery. J. Urol. 2001 Feb; 165(2): 513-4. PMID: 11176411, PII: S0022-5347(05)66737-7, DOI: 10.1097/00005392-200102000-00040, ISSN: 0022-5347.

Clark PE, Klein EA. Surgery for invasive bladder tumors: technique and outcome. Curr Opin Urol. 1999 Sep; 9(5): 413-8. PMID: 10579079, ISSN: 0963-0643.

Uzzo RG, Rayman P, Kolenko V, Clark PE, Cathcart MK, Bloom T, Novick AC, Bukowski RM, Hamilton T, Finke JH. Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells. J. Clin. Invest. 1999 Sep; 104(6): 769-76. PMID: 10491412, PMCID: PMC408430, DOI: 10.1172/JCI6775, ISSN: 0021-9738.

Uzzo RG, Rayman P, Kolenko V, Clark PE, Bloom T, Ward AM, Molto L, Tannenbaum C, Worford LJ, Bukowski R, Tubbs R, Hsi ED, Bander NH, Novick AC, Finke JH. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Clin. Cancer Res. 1999 May; 5(5): 1219-29. PMID: 10353760, ISSN: 1078-0432.

Uzzo RG, Clark PE, Rayman P, Bloom T, Rybicki L, Novick AC, Bukowski RM, Finke JH. Alterations in NFkappaB activation in T lymphocytes of patients with renal cell carcinoma. J. Natl. Cancer Inst. 1999 Apr 4/21/1999; 91(8): 718-21. PMID: 10218511, ISSN: 0027-8874.

Clark PE, Streem SB, Geisinger MA. 13-year experience with percutaneous management of upper tract transitional cell carcinoma. J. Urol. 1999 Mar; 161(3): 772-5; discussion 775. PMID: 10022682, PII: S0022-5347(01)61765-8, ISSN: 0022-5347.

Capelouto CC, Clark PE, Ransil BJ, Loughlin KR. A review of scrotal violation in testicular cancer: is adjuvant local therapy necessary?. J. Urol. 1995 Mar; 153(3 Pt 2): 981-5. PMID: 7853587, ISSN: 0022-5347.